Cite
MLA Citation
Josep Tabernero et al.. “Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer.” Oncologist, vol. 20, 2015, pp. 143–150. http://access.bl.uk/ark:/81055/vdc_100150612259.0x00002f